# LiGeR-HN1

Source: https://onco.cc/trials/liger-hn1/  
OnCo record `liger-hn1` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Tests whether a two-armed antibody against EGFR and a stem-cell marker can lift first-line immunotherapy results in head and neck cancer.

## Summary

Phase 2 petosemtamab + pembrolizumab reported ORR ~63% in first-line PD-L1-positive HNSCC (ASCO 2025), far above pembrolizumab's historical ~19-23%. LiGeR-HN1 (first line, includes HPV-positive disease) and LiGeR-HN2 (second line, monotherapy vs chemotherapy) are the registrational trials; interim analyses expected 2026-27.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-07
- Registry id: NCT06525220
- Phase: 3
- Setting: Untreated PD-L1-positive recurrent or metastatic HNSCC: petosemtamab + pembrolizumab vs pembrolizumab
- Sponsor: Merus (Genmab)

## Sources

- ClinicalTrials.gov NCT06525220: https://clinicaltrials.gov/study/NCT06525220

## Connected records

- cancers: [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/), [Recurrent or metastatic head and neck squamous cell carcinoma](https://onco.cc/cancers/recurrent-metastatic-hnscc/)
- technologies: [Bispecific antibodies](https://onco.cc/technologies/bispecific-antibody/)
- targets: [EGFR](https://onco.cc/targets/egfr/)
- terms: [LGR5](https://onco.cc/terms/lgr5/)
- drugs: [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/), [Petosemtamab](https://onco.cc/drugs/petosemtamab/)
- companies: [Genmab](https://onco.cc/companies/genmab/), [Merus](https://onco.cc/companies/merus/)
- pairings: [EGFR-directed bispecific + PD-1 blockade](https://onco.cc/pairings/egfr-bispecific-plus-pd1-hnscc/)

---
JSON: https://onco.cc/api/v1/entities/liger-hn1.json